Circulating TP53 mutations are associated with early tumor progression and poor survival in pancreatic cancer patients treated with FOLFIRINOX.
Fleur van der SijdeZakia AzmaniMarc G BesselinkBert A BonsingJan Willem B de GrootBas Groot KoerkampBrigitte C M HaberkornMarjolein Y V HomsWilfred F J Van IJckenQuisette P JanssenMartijn P LolkemaSaskia A C LuelmoLeonie J M MekenkampDana A M MustafaRon H N van SchaikJohanna W WilminkEveline E VietschCasper H J van EijckPublished in: Therapeutic advances in medical oncology (2021)
The combination of a TP53 ctDNA mutation before start of FOLFIRINOX and a homozygous TP53 Pro72Arg variant is a promising biomarker, associated with early tumor progression during FOLFIRINOX and poor OS. The results of this exploratory study need to be validated in an independent cohort.